InnoCare Pharma Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INCPF research report →
Companywww.innocarepharma.com
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma.
- CEO
- Jisong Cui
- IPO
- 2021
- Employees
- 1,089
- HQ
- Beijing, CN
Price Chart
Valuation
- Market Cap
- $2.32B
- P/E
- 25.97
- P/S
- 6.34
- P/B
- 2.55
- EV/EBITDA
- 17.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.36%
- Op Margin
- 23.70%
- Net Margin
- 28.78%
- ROE
- 10.12%
- ROIC
- 6.18%
Growth & Income
- Revenue
- $2.30B · 127.62%
- Net Income
- $625.89M · 242.04%
- EPS
- $0.36 · 238.46%
- Op Income
- $440.63M
- FCF YoY
- 129.48%
Performance & Tape
- 52W High
- $3.26
- 52W Low
- $1.55
- 50D MA
- $1.55
- 200D MA
- $2.27
- Beta
- 0.35
- Avg Volume
- 16
Get TickerSpark's AI analysis on INCPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our INCPF Coverage
We haven't published any research on INCPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INCPF Report →